Our 325,000ft² facility can manufacture up to 3 billion units. We supply oral pharmaceuticals to the U.S. market using our expertise in controlled release granules, serialization, blister and bottle packaging, powder packaging in stick packs, fluid bed operations, solvent processing, DEA controlled substances, high potency active ingredients and nanoparticle milling.
OUR CAPABILITIES
MEET OUR TEAM
Learn more about Frontida through the expertise
and insight from our management team.
DuraGran®
Our fluid bed processing technology reduces production times by combining particle sizing and coating processes together, eliminating the need for extrusion and spheronization for high API-loaded drug particulates.
AdaptDose™
Our unique commercialized approach to adaptive formulation design provides the ability to combine multiple active ingredients and/or delivery rates in a single capsule using minitabs, beads, granules and liquids. Also appropriate for dose escalation studies.
Team Member Perspectives
I have been working in the pharmaceutical industry in various departments of manufacturing for 30 years. I am very excited and privileged to work with the new team formed by Frontida BioPharm. I am committed to portray the Frontida motto of caring for our clients by maintaining a high level of quality products and services for each of our customers.
We are highly motivated and determined to provide the highest quality products. I am proud to be a Frontida employee, working amongst a great team of caring, committed people. I look forward to new business opportunities and exciting challenges in the road ahead.
Frontida brings new life to its employees with positive motivation and improvements. New management is constantly adapting new ideas to improve the quality of our work.
Working for Frontida is a pleasure. We are all working towards the same goal: to support our clients and make quality products for the consumers who need the medications made at the site.
NEWS & UPDATES
Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities
Highly potent compounds serve an increasingly significant role in numerous R&D landscapes and pharmaceutical intensive medical treatments; i.e. oncology, atrial fibrillation, osteoporosis.
FB-HRS, LLC Announces US FDA Clearance of IND Application to Initiate Clinical Trial for FBHRS001, a Treatment for Atrial Fibrillation
Atrial Fibrillation impacts a tremendous amount of people around the world and current treatment options are underwhelming due to negative side effects. FB–HRS, LLC has developed a treatment that may reduce those undesired consequences.